Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional dexamethasone injections changes burning sensation (VAS 0-100) compared with placebo injections (very low certainty).
2 findings from 1 review
MD -52.00 [-62.04, -41.96]
1 study · 25 participants
Very low
MD -46.00 [-53.44, -38.56]
1 study · 25 participants
Very low
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Quality of life · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Difficulty in mouth opening (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) led to lower difficulty in mouth opening (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Difficulty in swallowing (participant-reported proxy) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Antioxidants (lycopene, curcumin, Oxitard) led to lower difficulty in swallowing (participant-reported proxy) compared with placebo or no active treatment; GRADE not reported.
1 finding from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether pentoxifylline changes burning sensation (VAS 0-100) compared with placebo or no active treatment (very low certainty).
1 finding from 1 review
Economic: direct costs · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
The review found no eligible studies for this question.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether hydrocortisone plus hyaluronidase (intralesional) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
1 finding from 1 review
Chemotherapy vs Placebo
Outcome not reported · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
The review found no eligible studies for this question.
1 finding from 1 review
Candidosis (adverse effect) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Reduction in pain · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical corticosteroid showed no clear difference in clinical score compared with placebo (low certainty).
1 finding from 1 review
Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical corticosteroid changes clinical resolution compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical corticosteroid changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical corticosteroid may leads to higher pain resolution compared with placebo (low certainty).
1 finding from 1 review
Pain (mean score, 0-10) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical corticosteroid may leads to lower pain (mean score, 0-10) compared with placebo (low certainty).
1 finding from 1 review